Floatz logo

Lucitanib

Gynecologic Cancer

Clovis Oncology, Inc.Small moleculePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

52 Active assets in the Gynecologic Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Lucitanib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →